Appajosyula Sireesh purchased $100K of CTRVP
Appajosyula Sireesh (Chief Operating Officer) purchased 2,000,000 shares of Hepion Pharmaceuticals, Inc. (CTRVP) at $0.05 ($0.10M total) on 2026-08-03.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the COO’s open-market purchase of 2,000,000 shares at $0.0500, totaling $100,000, with post-transaction holdings of 3,250,000 shares.
Market read
Traders may treat this as a mild sentiment input, but it does not introduce new operational or financial information about Hepion.
What to watch
The article provides no context on whether the purchase price is favorable versus recent trading levels, nor any concurrent company catalysts.
Background
The article is an SEC Form 4 insider transaction disclosure for Hepion Pharmaceuticals, Inc.
Ticker impact
Form 4 shows COO Appajosyula Sireesh bought 2,000,000 shares of Hepion Pharmaceuticals at $0.0500 on 2026-08-03 for $100,000.
Likely limited near-term impact; any effect is more sentiment-driven than event-driven.
The filing is a routine insider transaction with no 10b5-1 plan and no accompanying company-specific operational update in the text.
Market effects
No sector-wide read-through is provided; this is company-specific insider activity only.
None indicated.
None indicated.
Counterpoint
Insider buys can be driven by liquidity needs, diversification, or non-informational motives, especially without a stated rationale in the filing.
Key entities
- issuerHepion Pharmaceuticals, Inc.
Subject of the Form 4 insider transaction disclosure (ticker CTRVP).
- insiderAppajosyula Sireesh
Chief Operating Officer who reported the open-market purchase.